BIO vs CERS
BIO: A multinational life science and clinical diagnostics company providing research tools, diagnostic test systems, and consumables to laboratories and biopharmaceutical manufacturers worldwide. CERS: Cerus develops pathogen-inactivation technologies for blood transfusions and cellular therapy products, with the INTERCEPT Blood System as its lead commercial offering.
Side-by-side fundamentals
| Metric | BIO | CERS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $305.96 | $3.02 | |
| Market cap as of 2026-07-23 | $8.2B | $625M | |
| P/E as of 2026-07-23 | 48.82 | n/a | |
| Net margin as of 2026-07-23 | +6.5% | -3.9% | BIO higher |
| Gross margin as of 2026-07-23 | +51.8% | +58.4% | CERS higher |
| Operating margin as of 2026-07-23 | +2.0% | -1.3% | BIO higher |
| ROE as of 2026-07-23 | +2.4% | -15.4% | BIO higher |
| ROA as of 2026-07-23 | +1.7% | -4.4% | BIO higher |
| Debt / equity as of 2026-07-23 | 0.18 | 1.26 | BIO lower |
| Revenue growth (YoY) as of 2026-07-23 | +1.9% | +18.4% | CERS higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | +7.5% | CERS higher |
| Beta as of 2026-07-23 | 1.06 | 1.75 | |
| 1-year return as of 2026-07-22 close | +24.6% | +111.2% | CERS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.